Search Results - "Kolbin, A S"

Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma by Kolbin, A S, Avdeev, S N, Zhuravleva, M V, Gomon, Yu M, Balykina, Yu E, Matveyev, N V, Proskurin, M A, Fedosenko, S V

“…Asthma is a heterogeneous chronic disease of airways. One of its endotypes is eosinophilic asthma, accompanied by both peripheral blood and airway…”
Get full text

Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children by Kolbin, A. S., Kasimova, A. R.

“…Objective : to perform pharmacoeconomic analysis of the feasibility of using topical bacterial lysate in the form of nasal spray (IRS®19) for the treatment and…”
Get full text

Clinical and economic assessment of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory tract infections in children by Kasimova, A. R., Kolbin, A. S.

“…Objective : pharmacoeconomic analysis of the feasibility of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory…”
Get full text

An early assessment of the efficacy of medicines in the treatment of patients with COVID-19 by Kolbin, A. S.

“…Coronavirus infection 2019 is considered a modern challenge to the world community. In the absence of vaccines and antivirals, effective and safe medicines are…”
Get full text

Evidence-based medicine: new in the search for evidence by Verbitskaya, E. V., Belousov, D. Yu, Kolbin, A. S.

“…The review is focused on discussing new trends in DM, rethinking the evidence base medicine with an emphasis on demonstrating the efficacy and safety of new…”
Get full text

External control during RWD/RWE research: a methodological approach by Zhuravkov, A. A., Kolbin, A. S.

“…At the moment, randomized controlled trials (RCTs) are the gold standard for providing evidence of the effectiveness and safety of medicines. If it is…”
Get full text

Socio-economic burden of atrial fibrillation in the Russian Federation: dynamics over 12 years by Kasimova, A. P., Tufanova, O. S., Kolbin, A. S.

“…Relevance. Diseases of the cardiovascular system remain one of the main causes of death worldwide. The incidence of cardiovascular and circulatory diseases…”
Get full text

Nonsteroidal anti-inflammatory drugs’ adverse drug reactions: 10 years of national database data by Syraeva, G. I., Kolbin, A. S.

“…The group of non-steroidal anti-inflammatory drugs has occupied one of the leading positions in terms of demand by the population over the past decade. This…”
Get full text

Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation by Kolbin, A. S., Kasimova, A. R., Gilyarevskiy, S. R.

“…Aim. To compare the effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (AF) for preventing stroke and…”
Get full text

Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases by Kolbin, A. S., Kasimova, A. R., Gilyarevskiy, S. R.

“…Aim. To conduct a pharmacoeconomic analysis of the use of the drug Eliquis® (apixaban), belonging to direct oral anticoagulants (DOACs), for the treatment and…”
Get full text

Quantitative Signal Detection for COVID-19 Medicinal Products Based on Retrospective Analysis of Spontaneous Reports from the Russian Pharmacovigilance Database by Mishinova, S. A., Kolbin, A. S., Polushin, Yu. S., Verbickaya, E. V.

“…SCIENTIFIC RELEVANCE. The pandemic of novel coronavirus infection (COVID-19) led to a drastic increase in the use of medicinal products of various therapeutic…”
Get full text

Updated guidelines of reporting pharmacoeconomics and health technology assessment results from 2022 ISPOR (CHEERS 2022) by Truuts, M. A., Kurilev, A. A., Kolbin, A. S.

“…In 2022, ISPOR released an updated checklist on economic evaluation of health care, since the latter several years have passed, the circumstances have changed,…”
Get full text

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study by Kolbin, A. S., Gomon, Yu. M., Proskurin, M. A., Balykina, Yu. E.

“…Objective: to evaluate the clinical and economic effectiveness of alectinib in comparison with lorlatinib in adult patients with advanced anaplastic lymphoma…”
Get full text

Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg by Kurylev, A. A., Zhuravkov, A. A., Kolbin, A. S.

“…Introduction. To date, 20 COVID-19 vaccines have been registered and used in the world, three of them have been developed in the Russian Federation. The…”
Get full text

A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy by Yu. M. Gomon, A. S. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. M. Sultanova, Yu. E. Balykina

“…Aim. Evaluation of the effectiveness of anti-interleukin drugs used in the pathogenetic therapy of COVID-19 in relation to the relative risks of 28-day…”
Get full text

Pragmatic clinical trials by Shevchenko, O. R., Kolbin, A. S.

“…Pragmatic clinical trials (PCTs) allow combining the advantages of observational trials in real-world evidence with the scientific rigor of randomized clinical…”
Get full text

Quantitative and qualitative evaluation of the use of nonsteroidal anti-inflammatory drugs in the Russian Federation over 10 years by Syraeva, G. I., Kolbin, A. S., Mishinova, S. A., Kalyapin, A. A.

“…Relevance. Studies devoted to the assessment of consumption, as well as to the issues of pharmacosafety of nonsteroidal anti-inflammatory drugs, are limited at…”
Get full text

Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity by Kasimova, A. R., Kolbin, A. S., Proskurin, M. A., Balykina, Yu. E.

“…Background. Chronic lymphocytic leukemia (CLL) is a b-cell tumor of small b-lymphocytes. In CLL, significant lymphocytosis (5000 monoclonal b-lymphocytes) is…”
Get full text

The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults by Kolbin, A. S., Kurilev, A. A., Balikina, Y. E., Proskurin, M. A.

“…Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100…”
Get full text

Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults by Kolbin, A. S., Gomon, Y. M., Proskurin, M. A., Balikina, Y. E.

“…Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal…”
Get full text